Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
170.86
+0.89 (0.52%)
At close: Jun 27, 2025, 4:00 PM
171.80
+0.94 (0.55%)
After-hours: Jun 27, 2025, 7:28 PM EDT
BDX Revenue
Becton, Dickinson and Company had revenue of $5.27B in the quarter ending March 31, 2025, with 4.50% growth. This brings the company's revenue in the last twelve months to $20.87B, up 5.84% year-over-year. In the fiscal year ending September 30, 2024, Becton, Dickinson and Company had annual revenue of $20.18B with 4.16% growth.
Revenue (ttm)
$20.87B
Revenue Growth
+5.84%
P/S Ratio
2.33
Revenue / Employee
$285,849
Employees
73,000
Market Cap
48.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BDX News
- 2 days ago - Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now - Benzinga
- 3 days ago - Best Dividend Kings: June 2025 - Seeking Alpha
- 18 days ago - Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 18 days ago - Becton, Dickinson: A Dividend King Facing Challenges Offers Value - Seeking Alpha
- 20 days ago - June's Top Dividend Aristocrat Fat Pitches: Blue-Chip Bargains You Can't Miss - Seeking Alpha
- 23 days ago - June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs - Seeking Alpha
- 4 weeks ago - BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - PRNewsWire
- 4 weeks ago - Best Dividend Aristocrats For June 2025 - Seeking Alpha